Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity

Quotti Tubi, Laura; Gurrieri, Carmela; Brancalion, Alessandra; Bonaldi, Laura; Bertorelle, Roberta; Manni, Sabrina; Pavan, Laura; Lessi, Federica; Zambello, Renato; Trentin, Livio; Adami, Fausto; Ruzzene, Maria; Pinna, Lorenzo A; Semenzato, Gianpietro; Piazza, Francesco

doi:10.1186/1756-8722-6-78

Table 1 Features of controls and AML cases analyzed

From: Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity

		Sample type	ELN risk group	Karyotype	Molecular alterations	% CD 34 positive cells
1	bm	Healthy donor	-	46,XY	-	NA
2	pb	AML patient	Fav	46:xy	NPM1, FLT3 normal, CEBPA mut	60%
3	bm	AML patient	Fav	46,XX,t(15;17)(q22;q11)[24]/46,XX[1] 96% of altered methaphases	PML/RARα	CD34-
4	pb	AML patient	Int-I	46,XY	NPM1 mut (mut A), FLT3 mut	CD34-
5	bm	AML patient	Int-I	46,XY	NPM1and FLT3 normal	82%
6	pb	AML patient	Int-II	47,XY,+19[13]/47,XY,+del(1)(p13)[3]/46,XY[9] 64% of altered methaphases	NPM1 mut (Mut A), FLT3 mut	52%
7	pb	AML patient	Int-II	46,XX,del(1)(p33)[6]/46,XX[1] 86% of altered methaphases	NPM1 mut (mut A), FLT3 normal	CD34-
8	pb	AML patient	Adv	Complex karyotype 100% of altered methaphases	-	78%
9	bm	AML patient	Adv	Complex karyotype 100% of altered methaphases	NPM1and FLT3 normal	89%
10	NB4	AML Cell line	-	-		CD34-
11	ML2	AML Cell line	-	-	PML/RARα	CD34-
12	ME-1	AML Cell line	-	-	-	100%
13	pb	Healthy donor	-	46,XY	-	NA
14	bm	AML patient	Fav	46,XY	NPM1 mut (MUT K) FLT3 normal	27%
15	pb	AML patient	Fav	46,XY		CD34-
16	bm	AML patient	Fav	46,XX	NPM1 Mut (Mut C), FLT3 norm	CD34-
17	pb	AML patient	Int-I	46,XY	NPM1 mut (Mut A),FLT3 mut	48%
18	apheresis	AML patient	Int-I	46,XY	NPM1 mut (Mut A),FLT3 mut	83%
19	pb	AML patient	Int-I	46,XX	NPM1 mut (Mut B), FLT3 mut	10%
20	bm	AML patient	Int-I	46,XY	NPM1 norm, FLT3 mut	CD34-
21	pb	AML patient	Int-II	46,XX	FLT3 mut (+75 ITD), NPM1 normal	CD34-
22	pb	Healthy donor	-	46,XY	-	NA
23	pb	AML patient	Fav	46,XY	NPM1 and FLT3 normal	CD34-
24	pb	AML patient	Fav	46,XX	NPM1and FLT3 normal	CD34-
25	bm	AML patient	Int-I	46,XX	FLT3 mut (+75 ITD), NPM1 norm	22%
26	pb	AMLpatient	Int-I	46,XY	FLT3 mut, NPM1 norm	40%
27	pb	AML patient	Int-I	46,XX	NPM1and FLT3 normal	72%
28	pb	AML patient	Int-I	46,XY	NPM1 mut (mut A), FLT3 mut	CD34-
29	pb	AML patient	Int-I	46,XX	NPM1and FLT3 normal	33%
30	pb	AML patient	Int-II	46,XX,del(1)(p33)[6]/46,XX[1] 86% of altered methaphases	NPM1 mut (mut A), FLT3 normal	CD34-
31	bm	AMLpatient	Int-II	46,XY,t(12;17)(p13;q21)[9]/46,XY[1] 90% of altered methaphases	FLT3 mut (+8 ITD), NPM1 norm	87%
32	pb	AML patient	adv	46,XY,der(8)t(8;?)(p11;?)[20] 100% of altered methaphases	NPM1and FLT3 normal	89%
33	pb	AML patient	adv	Complex karyotype 100% of altered methaphases	NA	78%
34	pb	Healthy donor	-	46,XY	-	NA
35	bm	AML patient	Int-II	46,XY,der(8)t(8;?)(p11;?)[20] 100% of altered methaphases	NPM1and FLT3 normal	76%
36	pb	AML patient	Int-II	NA	NA	90%
37	bm	AML patient	Int-II	NA	NA	95%
38	pb	AML patient	Adv	NA	NA	CD34-

Cases were progressively numbered according to loading order in the immunoblot gels. BM = bone marrow; PB =peripheral blood; FAV = favourable; INT-I = intermediate I; INT-II = intermediate II; ADV = adverse [according to the ELN risk stratification (Rollig et al. 2011, Journal of Clinical Oncology 29;2758)]; NA = not assessed; MUT = mutated.

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com

Journal of Hematology & Oncology

Contact us